Updated:
Aglaia Oncology Funds
Aglaia invests in oncology drug development companies and selects and matures early-stage breakthrough inventions with the potential to transform cancer...
Overview
Aglaia invests in oncology drug development companies and selects and matures early-stage breakthrough inventions with the potential to transform cancer treatment. The team has decades of experience in cancer research and oncology drug development. Since 2004, Aglaia has built a reputation starting up biotech companies focused on oncology drug development. Aglaia has invested in 12 early stage companies, of which 6 were founded by Aglaia, and brings hands-on experience designing R&D plans from early screening through clinical studies.
General information
Firm type
Private Equity
Year founded
2003
Location
Region
Europe
Country
Netherlands
City
Bilthoven
Corporate office
Bilthoven, Netherlands
Principals
Karl Rothweiler
Partner
Folkert van Cleef
Partner
Eric van der Putten
Partner
Mark Krul
Partner
Ernst Geutjes
Venture Partner
Sector focus
Frequently asked questions
What stages does Aglaia Oncology Funds target?
The firm focuses on early stage, seed, start-up, and spin-off opportunities.
Which sectors receive capital from Aglaia Oncology Funds?
Investments center on oncology and related life sciences areas.
Does Aglaia Oncology Funds commit to external funds or direct deals?
Available information shows a venture strategy without specified fund or direct allocation split.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: